Anti-tumour necrosis factor agent and liver injury: Literature review, recommendations for management

EASL Clinical Practical Guidelines: Management of Alcoholic Liver Disease

(2015)   JOURNAL OF HEPATOLOGY

EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection

(2015)   JOURNAL OF HEPATOLOGY

Liver Injury From Tumor Necrosis Factor-α Antagonists: Analysis of Thirty-four Cases

(2013) Marwan Ghabril et al.   Clinical Gastroenterology and Hepatology

Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis

(2013) William J. Sandborn et al.   GASTROENTEROLOGY

Hepatic histological findings in suspected drug-induced liver injury: Systematic evaluation and clinical associations

(2013) David E. Kleiner et al.   HEPATOLOGY

Tumor Necrosis Factor Inhibitors for Inflammatory Bowel Disease

(2013) Ole Haagen Nielsen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hépatite induite par l’infliximab lors du traitement d’une maladie de Crohn vulvaire

(2012) S. Caussé et al.   ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE

A case report: Ulcerative colitis, treatment with an antibody against tumor necrosis factor (infliximab), and subsequent liver necrosis

(2012) Urpo Kinnunen et al.   Journal of Crohns & Colitis

Adalimumab in prevention of postoperative recurrence of Crohn's disease in high-risk patients

(2012) Mariam Aguas   WORLD JOURNAL OF GASTROENTEROLOGY

Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis

(2011) X. Mariette et al.   ANNALS OF THE RHEUMATIC DISEASES

Infliximab Induces Increase in Triglyceride Levels in Psoriatic Arthritis Patients

(2011) Karla R. Castro et al.   Clinical & Developmental Immunology

Infliximab-Induced Autoimmune Hepatitis with Successful Switch to Adalimumab in a Patient with Crohn’s disease: The Index Case

(2011) Dahlia A. Goldfeld et al.   DIGESTIVE DISEASES AND SCIENCES

Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management

(2011) Mauro Viganò et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis

(2011) William J. Sandborn et al.   GASTROENTEROLOGY

Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

(2011) W. Reinisch et al.   GUT

Guidelines for the management of inflammatory bowel disease in adults

(2011) C. Mowat et al.   GUT

Infliximab-induced autoimmune hepatitis in Crohnʼs disease treated with budesonide and mycophenolate

(2011) K. Subramaniam et al.   INFLAMMATORY BOWEL DISEASES

Scheduled infliximab monotherapy to prevent recurrence of Crohnʼs disease following ileocolic or ileal resection: A 3-year prospective randomized open trial

(2011) Koji Yoshida et al.   INFLAMMATORY BOWEL DISEASES

Autoimmune hepatitis during infliximab therapy for Crohn's disease: A case report

(2011) Adam Doyle et al.   Journal of Crohns & Colitis

Review article: clinically significant liver injury in patients treated with natalizumab (TYSABRI™)

(2010) S. BEZABEH et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Autoimmune Hepatitis Induced by Infliximab in a Patient with Crohnʼs Disease with no Relapse After Switching to Adalimumab

(2010) Marilia Cravo et al.   BIODRUGS

Continuous Therapy With Certolizumab Pegol Maintains Remission of Patients With Crohn's Disease for up to 18 Months

(2010) Gary R. Lichtenstein et al.   Clinical Gastroenterology and Hepatology

The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in Inflammatory Bowel Disease☆

(2010) Ambrogio Orlando et al.   DIGESTIVE AND LIVER DISEASE

Infliximab-induced acute hepatitis during Crohn's disease therapy: Absence of cross-toxicity with adalimumab

(2010) A. Haennig et al.   GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE

Standardization of nomenclature and causality assessment in drug-induced liver injury: Summary of a clinical research workshop

(2010) Robert J. Fontana et al.   HEPATOLOGY

Infliximab-related hepatitis: discussion of a case and review of the literature

(2010) Stefano Mancini et al.   Internal and Emergency Medicine

A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease

(2010) W. Miehsler et al.   Journal of Crohns & Colitis

Autoimmune hepatitis in two psoriasis patients treated with inflixmab

(2010) Catherine Goujon et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Autoimmune hepatitis associated with infliximab in a patient with palmoplantar pustular psoriaisis

(2009) D. A. Fairhurst et al.   CLINICAL AND EXPERIMENTAL DERMATOLOGY

Toxic hepatitis induced by infliximab in a patient with rheumatoid arthritis with no relapse after switching to etanercept

(2009) K. M. Carlsen et al.   CLINICAL RHEUMATOLOGY

Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease

(2009) Ioannis E. Koutroubakis et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab

(2009) William J. Sandborn et al.   GASTROENTEROLOGY

Etanercept tolerance in a patient with previous infliximab-induced hepatitis

(2008) Heidemarie Becker et al.   CLINICAL RHEUMATOLOGY

Causes, Clinical Features, and Outcomes From a Prospective Study of Drug-Induced Liver Injury in the United States

(2008) Naga Chalasani et al.   GASTROENTEROLOGY

Infliximab-induced hepatitis: absence of cross-toxicity with etanercept

(2008) Gérard Thiéfin et al.   JOINT BONE SPINE

Use of Tumor Necrosis Factor-α Inhibitors in Patients with Chronic Hepatitis B Infection

(2008) Matthew B. Carroll et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM